Drugs & Aging

, Volume 5, Issue 5, pp 358–365 | Cite as

The Role of Interleukin-6 in Certain Age-Related Diseases

  • William B. Ershier
  • Wen H. Sun
  • Neil Binkley
Clinical Pharmacology

Summary

Interleukin-6 (IL-6) is a pro-inflammatory cytokine with a wide range of functions. Perhaps the most important physiologically is its role as a mediator of the acute phase inflammatory response. Normally, there is little measurable IL-6 in the circulation, but levels increase abruptly to nanogram amounts during an inflammatory process. During aging, it has been proposed that the tight regulation of IL-6 gene expression becomes less effective and levels are measurable even when there is no evidence for inflammation. Several investigators have identified this cytokine as being involved in the pathogenesis of various disease processes and we have suggested that certain age-associated diseases are directly related. Among these are late-life lymphoma and myeloma, osteoporosis and possibly Alzheimer’s disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–78PubMedCrossRefGoogle Scholar
  2. 2.
    Ershler WB, Sun WH, Binkley N, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225–30PubMedGoogle Scholar
  3. 3.
    Pattengale PK, Firth CH. Contributions of recent research to the classification of spontaneous lymphoid cell neoplasms in mice. CRC Crit Revs Toxicol 1986; 16: 185–212CrossRefGoogle Scholar
  4. 4.
    Merz H, Fliedner A, Orscheschek K, et al. Cytokine expression in T-cell lymphomas and Hodgkin’s disease: its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am J Pathol 1991; 139: 1173–80PubMedGoogle Scholar
  5. 5.
    Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF/2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–5PubMedCrossRefGoogle Scholar
  6. 6.
    Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma —cell growth and differentiation by IL-6. Blood 1989; 73: 517–26PubMedGoogle Scholar
  7. 7.
    Asaoku H, Kawano M, Iwato K, et al. Decrease in BSF2/IL-6 response in advanced cases of multiple myeloma. Blood 1988; 72: 429–32PubMedGoogle Scholar
  8. 8.
    Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer’s disease due to an IL-1/IL-6-mediated ‘acute phase response’ in the brain? Immunol Today 1991; 12: 217–9PubMedCrossRefGoogle Scholar
  9. 9.
    Roodman GD. Interleukin-6: an osteotrophic factor? J Bone Miner Res 1992; 7: 475–8PubMedCrossRefGoogle Scholar
  10. 10.
    Girasole G, Jilka RL, Passen G. 17B-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89: 883–91PubMedCrossRefGoogle Scholar
  11. 11.
    Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88–91PubMedCrossRefGoogle Scholar
  12. 12.
    Seghal PB, Walther Z, Tamm I. Rapid enhancement of β2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci (USA) 1987; 84: 3633–5CrossRefGoogle Scholar
  13. 13.
    Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593–7PubMedCrossRefGoogle Scholar
  14. 14.
    Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gpl30. Cell 1989; 58: 573–81PubMedCrossRefGoogle Scholar
  15. 15.
    Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149–57PubMedCrossRefGoogle Scholar
  16. 16.
    Yasukawa K, Hirano T, Watanabe Y, et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987; 6: 2939–45PubMedGoogle Scholar
  17. 17.
    Tanabe O, Akira S, Kamiya T, et al. Genomic structure of the murine IL-6 gene: high degree of conservation of potential regulatory sequences between mouse and human. J Immunol 1988; 141: 3875–8PubMedGoogle Scholar
  18. 18.
    Tang B, Matsuda T, Akira S, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1990; 3: 273–8CrossRefGoogle Scholar
  19. 19.
    Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993; 23: 1078–82PubMedCrossRefGoogle Scholar
  20. 20.
    Effros RB, Svoboda K, Walford RL. Influence of age and caloric restriction on macrophage IL-6 and TNF production. Lymphokine Cytokine Res 1991; 10: 347–51PubMedGoogle Scholar
  21. 21.
    Zhou D, Chrest FJ, Adler W, et al. Increased production of TGF-beta and IL-6 by aged spleen cells. Immunol Lett 1993; 36: 7–12PubMedCrossRefGoogle Scholar
  22. 22.
    Foster KD, Conn CA, Kluger MJ. Fever, tumor necrosis factor and interleukin-6 in young, mature and aged Fischer 344 rats. Am J Physiol 1992; 262: R211–R215PubMedGoogle Scholar
  23. 23.
    Daynes RA, Araneo BA, Ershler WB, et al. A dysregulation in the production of interleukin-6 with normal aging: probable linkage to the age-associated depression in dehydroepiandrosterone (DHEA) and its sulfated derivative. J Immunol 1993; 150: 5219–30PubMedGoogle Scholar
  24. 24.
    Wei J, Xu H, Davies JL, et al. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1993; 51: 1953–6CrossRefGoogle Scholar
  25. 25.
    Sindermann J, Kruse A, Frercks H-J, et al. Investigations of the lymphokine system in elderly individuals. Mech Aging Dev 1993; 70: 149–59PubMedCrossRefGoogle Scholar
  26. 26.
    McKane R, Khosla S, Peterson J, et al. Effect of age and menopause on serum interleukin-6 levels in women. J Bone Miner Res 1993; 8 Suppl. 1: S157Google Scholar
  27. 27.
    Fagiolo U, Cossarizza A, Scala E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993; 23: 2375–8PubMedCrossRefGoogle Scholar
  28. 28.
    Goya RG, Gangerault M-C, DeMoraes MCL, et al. In vivo effects of growth factor on thymus function in aging mice. Brain Behav Immun 1992; 6: 341–54PubMedCrossRefGoogle Scholar
  29. 29.
    Liao Z, Caucino JA, Schnipper SM, et al. Increased urinary cytokines in the elderly. Aging Immunol Infect Dis 1993; 4: 139–53Google Scholar
  30. 30.
    Jourdan M, Bataille R, Seguin J, et al. Constitutive production of interleukin-6 and immunologic features in cardiac myxoma. Arthritis Rheum 1990; 33: 398–403PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–3PubMedGoogle Scholar
  32. 32.
    Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal carcinomas. FEBS Lett 1989; 250: 607–10PubMedCrossRefGoogle Scholar
  33. 33.
    Sakai A, Kawano M, Kuramoto A. Interleukin-6 produced by renal cell carcinoma cells and progression of multiple myeloma. N Engl J Med 1991; 324: 1893–4PubMedCrossRefGoogle Scholar
  34. 34.
    Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am GeriatrSoc 1993;41: 176–81Google Scholar
  35. 35.
    Volk MJ, Pugh TD, Kim MJ, et al. Dietary restriction from middle age attenuates age-associated lymphoma development and IL-6 dysregulation in C57BL/6 mice. Cancer Res 1994; 54: 3054–63PubMedGoogle Scholar
  36. 36.
    Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–26PubMedGoogle Scholar
  37. 37.
    Zhang XG, Bataille R, Widjenes J, et al. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992; 69: 1373–6PubMedCrossRefGoogle Scholar
  38. 38.
    Solary E, Guiguet M, Zeller V, et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am J Hematol 1992; 39: 163–71PubMedCrossRefGoogle Scholar
  39. 39.
    Bataille R, Jourdan M, Zhang XG, et al. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–11PubMedCrossRefGoogle Scholar
  40. 40.
    Ballester OF, Moscinski LC, Lyman GH, et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 1994; 83: 1903–8PubMedGoogle Scholar
  41. 41.
    Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin IL-6 levels are elevated in lymphoma patients and correlate with survival and advanced Hodgkin’s disease and with B symptoms. Cancer Res 1993; 53: 2118–22PubMedGoogle Scholar
  42. 42.
    Klein B, Lu ZY, Bataille R. Clinical applications of IL-6 inhibitors. Res Immunol 1992; 143: 774–6PubMedCrossRefGoogle Scholar
  43. 43.
    Klein B, Lu ZY, Gaillard JP, et al. Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol 1992; 182: 237–44PubMedCrossRefGoogle Scholar
  44. 44.
    Klein B, Wijdenes J, Zhang ZG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–204PubMedGoogle Scholar
  45. 45.
    Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory production by the antirheumatic agents Tenidap and Naproxen: a possible correlation with clinical acute phase response. J Immunol 1992; 148: 480–4PubMedGoogle Scholar
  46. 46.
    Wagge A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 1990; 20: 2439–43CrossRefGoogle Scholar
  47. 47.
    Mule JJ, Mclntosh JK, Jablons DM, et al. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 1990; 171: 629–36PubMedCrossRefGoogle Scholar
  48. 48.
    Sun WH, Pugh TD, Keller ET, et al. The anti-tumor activity of interleukin-6 in mice with immunogenic and non-immunogenic tumors. Int J Cancer. SubmittedGoogle Scholar
  49. 49.
    Sun WH, Kreisle RA, Phillips AW, et al. In vivo and in vitro characteristics of interleukin-6 transfected B16 melanoma cells. Cancer Res 1992; 52: 5412–5PubMedGoogle Scholar
  50. 50.
    Wong GG, Clark SC. Multiple actions of interleukin-6 within a cytokine network. Immunol Today 1988; 9: 137–9PubMedCrossRefGoogle Scholar
  51. 51.
    Bataille R, Klein B. The bone-resorbing activity of interleukin-6 [letter to the editor]. J Bone Miner Res 1991; 6: 1143–4PubMedCrossRefGoogle Scholar
  52. 52.
    Gowen M. The bone-resorbing activity of interleukin-6 [reply to letter to editor]. J Bone Miner Res 1991; 6: 1145–6CrossRefGoogle Scholar
  53. 53.
    Al-Humidan A, Ralston SH, Hughes DE, et al. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res 1991; 6: 3–8PubMedCrossRefGoogle Scholar
  54. 54.
    Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297–303PubMedGoogle Scholar
  55. 55.
    Kurihara N, Bertolini D, Suda T, et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 44: 4226–30Google Scholar
  56. 56.
    Black KS, Mundy GR, Garrett IR. Interleukin-6 causes hypercalcemia in vivo, and enhances the bone resorbing potency of interleukin-1 and tumor necrosis factor by two orders of magnitude in vitro. J Bone Miner Res 1991; 6 Suppl. 1: S271Google Scholar
  57. 57.
    Passeri G, Girasole G, Markus T, et al. 17b estradiol regulates IL-6 production and osteoclast development in murine cal varia cell cultures. J Bone Miner Res 1991: 6 Suppl. 1: S263Google Scholar
  58. 58.
    Greenfield EM, Gornik SA, Horowitz MC, et al. In vitro PTH increases both mRNA expression and IL-6 secretion from both osteoblast like cells and rat osteoblasts. J Bone Miner Res 1993; 8: 1163–71PubMedCrossRefGoogle Scholar
  59. 59.
    Balena R, Costantini F, Yamamoto M, et al. Mice with IL-6 gene knockout do not lose cancellous bone after ovariectomy. J Bone Miner Res 1993; 8 Suppl. 1: S130Google Scholar
  60. 60.
    Chaudhary LR, Speisberg TC, Riggs BL. Production of various cytokines by normal human osteoblast-like cells in response to interleukin 1b and tumor necrosis factor a: lack of regulation by 17 b-estradiol. Endocrinology 1993; 130: 2528–34CrossRefGoogle Scholar
  61. 61.
    Rifas L, Maricelli M, Kenney JS. IL-6 is not regulated by ovarian steroids in human bone marrow stromal cells and human osteoblasts with functional estrogen receptors. J Bone Miner Res 1993; 8 Suppl. 1: S361Google Scholar
  62. 62.
    Bellido T, Girasole, Passeri G, et al. Demonstration of estrogen receptors by western blot analysis in bone marrow stromal cells and osteoblasts: correlation with interleukin-6 regulation by estrogens and antiestrogens. J Bone Miner Res 1991; 6 Suppl. 1: S88Google Scholar
  63. 63.
    Girasole G, Passeri G, Knutson S, et al. Upregulation of osteoclastogenic potential of the marrow is induced by orchiectomy and is reversed by testosterone replacement in the mouse. J Bone Mineral Res 1992; 7 Suppl. 1: S96Google Scholar
  64. 64.
    Passeri G, Girasole G, Markus T, et al. 17b estradiol regulates IL-6 production and osteoclast development in murine calvaria cell cultures. J Bone Miner Res 1991; 6 Suppl. 1: S263Google Scholar
  65. 65.
    Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992; 256: 184–85PubMedCrossRefGoogle Scholar
  66. 66.
    Kosik KS. Alzheimer’s disease: a cell biological perspective. Science 1992; 256: 780–3PubMedCrossRefGoogle Scholar
  67. 67.
    Bauer J, König G, Strauss S, et al. In vitro matured macrophages express Alzheimer’s bA4-amyloid precursor protein indicating synthesis in microglial cells. FEBS Lett 1991; 282: 335–40PubMedCrossRefGoogle Scholar
  68. 68.
    Ganter U, Strauss S, Jonas U, et al. Alpha2-macroglobulin synthesis in interleukin-6-stimulated human neuronal (SHSY5Y neuroblastoma) cells: potential significance for the processing of Alzheimer b-amyloid precursor protein. FEBS Lett 1991; 282: 127–31PubMedCrossRefGoogle Scholar
  69. 69.
    Strauss S, Bauer J, Ganter U, et al. Detection of interleukin-6 and a2-macroglobulin immunoactivity in cortex and hippocampus of Alzheimer’s disease patients. Lab Invest 1992; 66: 223–30PubMedGoogle Scholar
  70. 70.
    Bauer J, Strauss S, Volk B, et al. IL-6-mediated events in Alzheimer’s disease pathology. Immunol Today 1992; 12: 422CrossRefGoogle Scholar
  71. 71.
    Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer’s disease due to an IL-1/IL-6-mediated ‘acute phase response’ in the brain? Immunol Today 1991; 12: 217–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • William B. Ershier
    • 1
  • Wen H. Sun
    • 1
  • Neil Binkley
    • 1
  1. 1.Section of Geriatrics, Department of Medicine, The Geriatrics Research, Education and Clinical Center (GRECC)The William S. Middleton Veterans Hospital, University of Wisconsin-MadisonWisconsinUSA

Personalised recommendations